ALX cuts two anti-CD47 programs just weeks after Gilead stopped a pivotal study of its own candidate

ALX On­col­o­gy is cut­ting two stud­ies of its an­ti-CD47 drug evor­pacept af­ter it failed to show sub­stan­tial ef­fi­ca­cy.

In its sec­ond-quar­ter re­port Thurs­day af­ter­noon, ALX said that it was wind­ing down stud­ies of evor­pacept in acute myeloid leukemia (AML) and its pre­cur­sor dis­ease, myelodys­plas­tic syn­dromes (MDS). In 45 pa­tients in the MDS study, the drug in com­bi­na­tion with chemother­a­py failed to do sub­stan­tial­ly bet­ter than chemother­a­py alone, ALX said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.